Report Detail

Request for Sample of this report

Pharma & Healthcare Global Endothelin Antagonists Therapeutics Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029

  • RnM4515470
    • |
  • 22 February, 2023
    • |
  • Global
    • |
  • 101 Pages
    • |
  • GIR (Global Info Research)
    • |
  • Pharma & Healthcare

According to our (Global Info Research) latest study, the global Endothelin Antagonists Therapeutics market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Endothelin are the type of therapeutics that inhibits the action of endothelin and is thus effective for treating pulmonary arterial hypertension. This receptor, which plays a major role in regulating vascular tone, is found between the lumen and underlying media of the pulmonary vasculature. For patients suffering from the pulmonary hypertension, the body secrete high amount of endothelin that causes the blood vessels to be constricted and increase in the BP in the pulmonary arteries.
This report is a detailed and comprehensive analysis for global Endothelin Antagonists Therapeutics market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Key Features:
Global Endothelin Antagonists Therapeutics market size and forecasts, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Endothelin Antagonists Therapeutics market size and forecasts by region and country, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Endothelin Antagonists Therapeutics market size and forecasts, by Type and by Application, in consumption value ($ Million), sales quantity (K Units), and average selling prices (US$/Unit), 2018-2029
Global Endothelin Antagonists Therapeutics market shares of main players, shipments in revenue ($ Million), sales quantity (K Units), and ASP (US$/Unit), 2018-2023
The Primary Objectives in This Report Are:
To determine the size of the total market opportunity of global and key countries
To assess the growth potential for Endothelin Antagonists Therapeutics
To forecast future growth in each product and end-use market
To assess competitive factors affecting the marketplace
This report profiles key players in the global Endothelin Antagonists Therapeutics market based on the following parameters - company overview, production, value, price, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Gilead Sciences, Inc, Sun Pharmaceutical Industries Ltd, Lupin, Zydus Group and Endo International plc, etc.
This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, COVID-19 and Russia-Ukraine War Influence.
Market Segmentation
Endothelin Antagonists Therapeutics market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of volume and value. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type
Oral
Parenteral
Market segment by Application
Cardiovascular Diseases
Scleroderma
Other
Major players covered
Gilead Sciences, Inc
Sun Pharmaceutical Industries Ltd
Lupin
Zydus Group
Endo International plc
Mylan NV
Teva Pharmaceutical Industries Ltd
Sigmapharm Laboratories , LLC
Alembic Pharmaceuticals Limited
Hikma Pharmaceuticals PLC
Amneal Pharmaceuticals LLC
AstraZeneca
Johnsons & Johnsons Private limited
GSK Plc
Market segment by region, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, United Kingdom, Russia, Italy, and Rest of Europe)
Asia-Pacific (China, Japan, Korea, India, Southeast Asia, and Australia)
South America (Brazil, Argentina, Colombia, and Rest of South America)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa, and Rest of Middle East & Africa)
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Endothelin Antagonists Therapeutics product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Endothelin Antagonists Therapeutics, with price, sales, revenue and global market share of Endothelin Antagonists Therapeutics from 2018 to 2023.
Chapter 3, the Endothelin Antagonists Therapeutics competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Endothelin Antagonists Therapeutics breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Endothelin Antagonists Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Endothelin Antagonists Therapeutics.
Chapter 14 and 15, to describe Endothelin Antagonists Therapeutics sales channel, distributors, customers, research findings and conclusion.


1 Market Overview

  • 1.1 Product Overview and Scope of Endothelin Antagonists Therapeutics
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Market Analysis by Type
    • 1.3.1 Overview: Global Endothelin Antagonists Therapeutics Consumption Value by Type: 2018 Versus 2022 Versus 2029
    • 1.3.2 Oral
    • 1.3.3 Parenteral
  • 1.4 Market Analysis by Application
    • 1.4.1 Overview: Global Endothelin Antagonists Therapeutics Consumption Value by Application: 2018 Versus 2022 Versus 2029
    • 1.4.2 Cardiovascular Diseases
    • 1.4.3 Scleroderma
    • 1.4.4 Other
  • 1.5 Global Endothelin Antagonists Therapeutics Market Size & Forecast
    • 1.5.1 Global Endothelin Antagonists Therapeutics Consumption Value (2018 & 2022 & 2029)
    • 1.5.2 Global Endothelin Antagonists Therapeutics Sales Quantity (2018-2029)
    • 1.5.3 Global Endothelin Antagonists Therapeutics Average Price (2018-2029)

2 Manufacturers Profiles

  • 2.1 Gilead Sciences, Inc
    • 2.1.1 Gilead Sciences, Inc Details
    • 2.1.2 Gilead Sciences, Inc Major Business
    • 2.1.3 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Product and Services
    • 2.1.4 Gilead Sciences, Inc Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.1.5 Gilead Sciences, Inc Recent Developments/Updates
  • 2.2 Sun Pharmaceutical Industries Ltd
    • 2.2.1 Sun Pharmaceutical Industries Ltd Details
    • 2.2.2 Sun Pharmaceutical Industries Ltd Major Business
    • 2.2.3 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product and Services
    • 2.2.4 Sun Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.2.5 Sun Pharmaceutical Industries Ltd Recent Developments/Updates
  • 2.3 Lupin
    • 2.3.1 Lupin Details
    • 2.3.2 Lupin Major Business
    • 2.3.3 Lupin Endothelin Antagonists Therapeutics Product and Services
    • 2.3.4 Lupin Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.3.5 Lupin Recent Developments/Updates
  • 2.4 Zydus Group
    • 2.4.1 Zydus Group Details
    • 2.4.2 Zydus Group Major Business
    • 2.4.3 Zydus Group Endothelin Antagonists Therapeutics Product and Services
    • 2.4.4 Zydus Group Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.4.5 Zydus Group Recent Developments/Updates
  • 2.5 Endo International plc
    • 2.5.1 Endo International plc Details
    • 2.5.2 Endo International plc Major Business
    • 2.5.3 Endo International plc Endothelin Antagonists Therapeutics Product and Services
    • 2.5.4 Endo International plc Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.5.5 Endo International plc Recent Developments/Updates
  • 2.6 Mylan NV
    • 2.6.1 Mylan NV Details
    • 2.6.2 Mylan NV Major Business
    • 2.6.3 Mylan NV Endothelin Antagonists Therapeutics Product and Services
    • 2.6.4 Mylan NV Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.6.5 Mylan NV Recent Developments/Updates
  • 2.7 Teva Pharmaceutical Industries Ltd
    • 2.7.1 Teva Pharmaceutical Industries Ltd Details
    • 2.7.2 Teva Pharmaceutical Industries Ltd Major Business
    • 2.7.3 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Product and Services
    • 2.7.4 Teva Pharmaceutical Industries Ltd Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.7.5 Teva Pharmaceutical Industries Ltd Recent Developments/Updates
  • 2.8 Sigmapharm Laboratories , LLC
    • 2.8.1 Sigmapharm Laboratories , LLC Details
    • 2.8.2 Sigmapharm Laboratories , LLC Major Business
    • 2.8.3 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Product and Services
    • 2.8.4 Sigmapharm Laboratories , LLC Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.8.5 Sigmapharm Laboratories , LLC Recent Developments/Updates
  • 2.9 Alembic Pharmaceuticals Limited
    • 2.9.1 Alembic Pharmaceuticals Limited Details
    • 2.9.2 Alembic Pharmaceuticals Limited Major Business
    • 2.9.3 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Product and Services
    • 2.9.4 Alembic Pharmaceuticals Limited Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.9.5 Alembic Pharmaceuticals Limited Recent Developments/Updates
  • 2.10 Hikma Pharmaceuticals PLC
    • 2.10.1 Hikma Pharmaceuticals PLC Details
    • 2.10.2 Hikma Pharmaceuticals PLC Major Business
    • 2.10.3 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Product and Services
    • 2.10.4 Hikma Pharmaceuticals PLC Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.10.5 Hikma Pharmaceuticals PLC Recent Developments/Updates
  • 2.11 Amneal Pharmaceuticals LLC
    • 2.11.1 Amneal Pharmaceuticals LLC Details
    • 2.11.2 Amneal Pharmaceuticals LLC Major Business
    • 2.11.3 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Product and Services
    • 2.11.4 Amneal Pharmaceuticals LLC Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.11.5 Amneal Pharmaceuticals LLC Recent Developments/Updates
  • 2.12 AstraZeneca
    • 2.12.1 AstraZeneca Details
    • 2.12.2 AstraZeneca Major Business
    • 2.12.3 AstraZeneca Endothelin Antagonists Therapeutics Product and Services
    • 2.12.4 AstraZeneca Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.12.5 AstraZeneca Recent Developments/Updates
  • 2.13 Johnsons & Johnsons Private limited
    • 2.13.1 Johnsons & Johnsons Private limited Details
    • 2.13.2 Johnsons & Johnsons Private limited Major Business
    • 2.13.3 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Product and Services
    • 2.13.4 Johnsons & Johnsons Private limited Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.13.5 Johnsons & Johnsons Private limited Recent Developments/Updates
  • 2.14 GSK Plc
    • 2.14.1 GSK Plc Details
    • 2.14.2 GSK Plc Major Business
    • 2.14.3 GSK Plc Endothelin Antagonists Therapeutics Product and Services
    • 2.14.4 GSK Plc Endothelin Antagonists Therapeutics Sales Quantity, Average Price, Revenue, Gross Margin and Market Share (2018-2023)
    • 2.14.5 GSK Plc Recent Developments/Updates

3 Competitive Environment: Endothelin Antagonists Therapeutics by Manufacturer

  • 3.1 Global Endothelin Antagonists Therapeutics Sales Quantity by Manufacturer (2018-2023)
  • 3.2 Global Endothelin Antagonists Therapeutics Revenue by Manufacturer (2018-2023)
  • 3.3 Global Endothelin Antagonists Therapeutics Average Price by Manufacturer (2018-2023)
  • 3.4 Market Share Analysis (2022)
    • 3.4.1 Producer Shipments of Endothelin Antagonists Therapeutics by Manufacturer Revenue ($MM) and Market Share (%): 2022
    • 3.4.2 Top 3 Endothelin Antagonists Therapeutics Manufacturer Market Share in 2022
    • 3.4.2 Top 6 Endothelin Antagonists Therapeutics Manufacturer Market Share in 2022
  • 3.5 Endothelin Antagonists Therapeutics Market: Overall Company Footprint Analysis
    • 3.5.1 Endothelin Antagonists Therapeutics Market: Region Footprint
    • 3.5.2 Endothelin Antagonists Therapeutics Market: Company Product Type Footprint
    • 3.5.3 Endothelin Antagonists Therapeutics Market: Company Product Application Footprint
  • 3.6 New Market Entrants and Barriers to Market Entry
  • 3.7 Mergers, Acquisition, Agreements, and Collaborations

4 Consumption Analysis by Region

  • 4.1 Global Endothelin Antagonists Therapeutics Market Size by Region
    • 4.1.1 Global Endothelin Antagonists Therapeutics Sales Quantity by Region (2018-2029)
    • 4.1.2 Global Endothelin Antagonists Therapeutics Consumption Value by Region (2018-2029)
    • 4.1.3 Global Endothelin Antagonists Therapeutics Average Price by Region (2018-2029)
  • 4.2 North America Endothelin Antagonists Therapeutics Consumption Value (2018-2029)
  • 4.3 Europe Endothelin Antagonists Therapeutics Consumption Value (2018-2029)
  • 4.4 Asia-Pacific Endothelin Antagonists Therapeutics Consumption Value (2018-2029)
  • 4.5 South America Endothelin Antagonists Therapeutics Consumption Value (2018-2029)
  • 4.6 Middle East and Africa Endothelin Antagonists Therapeutics Consumption Value (2018-2029)

5 Market Segment by Type

  • 5.1 Global Endothelin Antagonists Therapeutics Sales Quantity by Type (2018-2029)
  • 5.2 Global Endothelin Antagonists Therapeutics Consumption Value by Type (2018-2029)
  • 5.3 Global Endothelin Antagonists Therapeutics Average Price by Type (2018-2029)

6 Market Segment by Application

  • 6.1 Global Endothelin Antagonists Therapeutics Sales Quantity by Application (2018-2029)
  • 6.2 Global Endothelin Antagonists Therapeutics Consumption Value by Application (2018-2029)
  • 6.3 Global Endothelin Antagonists Therapeutics Average Price by Application (2018-2029)

7 North America

  • 7.1 North America Endothelin Antagonists Therapeutics Sales Quantity by Type (2018-2029)
  • 7.2 North America Endothelin Antagonists Therapeutics Sales Quantity by Application (2018-2029)
  • 7.3 North America Endothelin Antagonists Therapeutics Market Size by Country
    • 7.3.1 North America Endothelin Antagonists Therapeutics Sales Quantity by Country (2018-2029)
    • 7.3.2 North America Endothelin Antagonists Therapeutics Consumption Value by Country (2018-2029)
    • 7.3.3 United States Market Size and Forecast (2018-2029)
    • 7.3.4 Canada Market Size and Forecast (2018-2029)
    • 7.3.5 Mexico Market Size and Forecast (2018-2029)

8 Europe

  • 8.1 Europe Endothelin Antagonists Therapeutics Sales Quantity by Type (2018-2029)
  • 8.2 Europe Endothelin Antagonists Therapeutics Sales Quantity by Application (2018-2029)
  • 8.3 Europe Endothelin Antagonists Therapeutics Market Size by Country
    • 8.3.1 Europe Endothelin Antagonists Therapeutics Sales Quantity by Country (2018-2029)
    • 8.3.2 Europe Endothelin Antagonists Therapeutics Consumption Value by Country (2018-2029)
    • 8.3.3 Germany Market Size and Forecast (2018-2029)
    • 8.3.4 France Market Size and Forecast (2018-2029)
    • 8.3.5 United Kingdom Market Size and Forecast (2018-2029)
    • 8.3.6 Russia Market Size and Forecast (2018-2029)
    • 8.3.7 Italy Market Size and Forecast (2018-2029)

9 Asia-Pacific

  • 9.1 Asia-Pacific Endothelin Antagonists Therapeutics Sales Quantity by Type (2018-2029)
  • 9.2 Asia-Pacific Endothelin Antagonists Therapeutics Sales Quantity by Application (2018-2029)
  • 9.3 Asia-Pacific Endothelin Antagonists Therapeutics Market Size by Region
    • 9.3.1 Asia-Pacific Endothelin Antagonists Therapeutics Sales Quantity by Region (2018-2029)
    • 9.3.2 Asia-Pacific Endothelin Antagonists Therapeutics Consumption Value by Region (2018-2029)
    • 9.3.3 China Market Size and Forecast (2018-2029)
    • 9.3.4 Japan Market Size and Forecast (2018-2029)
    • 9.3.5 Korea Market Size and Forecast (2018-2029)
    • 9.3.6 India Market Size and Forecast (2018-2029)
    • 9.3.7 Southeast Asia Market Size and Forecast (2018-2029)
    • 9.3.8 Australia Market Size and Forecast (2018-2029)

10 South America

  • 10.1 South America Endothelin Antagonists Therapeutics Sales Quantity by Type (2018-2029)
  • 10.2 South America Endothelin Antagonists Therapeutics Sales Quantity by Application (2018-2029)
  • 10.3 South America Endothelin Antagonists Therapeutics Market Size by Country
    • 10.3.1 South America Endothelin Antagonists Therapeutics Sales Quantity by Country (2018-2029)
    • 10.3.2 South America Endothelin Antagonists Therapeutics Consumption Value by Country (2018-2029)
    • 10.3.3 Brazil Market Size and Forecast (2018-2029)
    • 10.3.4 Argentina Market Size and Forecast (2018-2029)

11 Middle East & Africa

  • 11.1 Middle East & Africa Endothelin Antagonists Therapeutics Sales Quantity by Type (2018-2029)
  • 11.2 Middle East & Africa Endothelin Antagonists Therapeutics Sales Quantity by Application (2018-2029)
  • 11.3 Middle East & Africa Endothelin Antagonists Therapeutics Market Size by Country
    • 11.3.1 Middle East & Africa Endothelin Antagonists Therapeutics Sales Quantity by Country (2018-2029)
    • 11.3.2 Middle East & Africa Endothelin Antagonists Therapeutics Consumption Value by Country (2018-2029)
    • 11.3.3 Turkey Market Size and Forecast (2018-2029)
    • 11.3.4 Egypt Market Size and Forecast (2018-2029)
    • 11.3.5 Saudi Arabia Market Size and Forecast (2018-2029)
    • 11.3.6 South Africa Market Size and Forecast (2018-2029)

12 Market Dynamics

  • 12.1 Endothelin Antagonists Therapeutics Market Drivers
  • 12.2 Endothelin Antagonists Therapeutics Market Restraints
  • 12.3 Endothelin Antagonists Therapeutics Trends Analysis
  • 12.4 Porters Five Forces Analysis
    • 12.4.1 Threat of New Entrants
    • 12.4.2 Bargaining Power of Suppliers
    • 12.4.3 Bargaining Power of Buyers
    • 12.4.4 Threat of Substitutes
    • 12.4.5 Competitive Rivalry
  • 12.5 Influence of COVID-19 and Russia-Ukraine War
    • 12.5.1 Influence of COVID-19
    • 12.5.2 Influence of Russia-Ukraine War

13 Raw Material and Industry Chain

  • 13.1 Raw Material of Endothelin Antagonists Therapeutics and Key Manufacturers
  • 13.2 Manufacturing Costs Percentage of Endothelin Antagonists Therapeutics
  • 13.3 Endothelin Antagonists Therapeutics Production Process
  • 13.4 Endothelin Antagonists Therapeutics Industrial Chain

14 Shipments by Distribution Channel

  • 14.1 Sales Channel
    • 14.1.1 Direct to End-User
    • 14.1.2 Distributors
  • 14.2 Endothelin Antagonists Therapeutics Typical Distributors
  • 14.3 Endothelin Antagonists Therapeutics Typical Customers

15 Research Findings and Conclusion

    16 Appendix

    • 16.1 Methodology
    • 16.2 Research Process and Data Source

    Summary:
    Get latest Market Research Reports on Endothelin Antagonists Therapeutics. Industry analysis & Market Report on Endothelin Antagonists Therapeutics is a syndicated market report, published as Global Endothelin Antagonists Therapeutics Market 2023 by Manufacturers, Regions, Type and Application, Forecast to 2029. It is complete Research Study and Industry Analysis of Endothelin Antagonists Therapeutics market, to understand, Market Demand, Growth, trends analysis and Factor Influencing market.

    Last updated on

    REPORT YOU MIGHT BE INTERESTED

    Purchase this Report

    		$3,480.00
    		$5,220.00
    		$6,960.00
    		2,780.52
    		4,170.78
    		5,561.04
    		3,229.44
    		4,844.16
    		6,458.88
    		542,392.80
    		813,589.20
    		1,084,785.60
    		290,823.60
    		436,235.40
    		581,647.20
    Credit card Logo
    Sample Question Discount Download PDF

    Related Reports

    Reason to Buy

    • Trusted By Leaders

      Top executives from leading companies purchase research reports from us. 

    • Shop With Confidence

      We assist you with all the pre-sales enquiries related to any report so that you can buy with confidence.

    • Customer Centric

      Need assistance related to your research requirements? We are just a phone call or an email away.

    • Personalized Solutions

      Our experienced research specialists are here to help you locate the right reports for your need.

    • Secure Checkout

      Shop without being worried about safety & security of your transactions.
      •

    Request for Sample of this report

    Reports and Markets

    mcafree

    Contact Us

    +1-352-353-0818 (US)

    info@reportsandmarkets.com

    Support

    EMAIL US

    Newsletter

    KEEP UP TO DATE ON ALL THE LATEST REPORTS


    maxmind_logo